ArticleBiosensors & bioelectronics2020
Force-dependent trans-endocytosis by breast cancer cells depletes costimulatory receptor CD80 and attenuates T cell activation.
Article in Biosensors & bioelectronics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Band-interface cooperative engineering of bismuth-based heterojunctions for sonodynamic-chemodynamic synergistic breast cancer therapy.Materials today. Bio · 2025Article
- Mechanical interactions impact the functions of immune cells and their application in immunoengineering.Advanced therapeutics · 2025Article
- Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential.Experimental hematology & oncology · 2025Review
- The role of immune checkpoint molecules in cancers.Frontiers in immunology · 2025Review
- The Trojan Horse Within: Mechanisms of Immune Evasion in Breast Cancer.Cancer heterogeneity and plasticity · 2025Article
- The Biological Significance of Trogocytosis.Results and problems in cell differentiation · 2024Article
- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells.Human cell · 2023Review
- Identification and validation of miR-583 and mir-877-5p as biomarkers in patients with breast cancer: an integrated experimental and bioinformatics research.BMC research notes · 2023Article
- Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures.International journal of molecular sciences · 2023Article
- Physical-Chemical Regulation of Membrane Receptors Dynamics in Viral Invasion and Immune Defense.Journal of molecular biology · 2023Review
- Measurement of Forces for Trans-Endocytosis at Dorsal and Ventral Sides of the Cell.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer.Frontiers in oncology · 2023Review
- T Cell engineering for cancer immunotherapy by manipulating mechanosensitive force-bearing receptors.Frontiers in bioengineering and biotechnology · 2023Review
- Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Recent developments in DNA-based mechanical nanodevices.Chemical communications (Cambridge, England) · 2022Review
- Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
In this study, we investigated the biophysical interaction between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CD80. CTLA-4 is a key molecule in immunosuppression, and CD80 is a costimulatory receptor promoting T cell activation. We observed that after cell-cell contact was established between breast cancer cells and antigen presenting cells (APCs), CTLA-4 expressed on the breast cancer cells bind to CD80 expressed on the APCs, and underwent trans-endocytosis to deplete CD80. Force measurement and live cell imaging revealed that upon binding to CD80, forces generated by breast cancer cells and transmitted via CTLA-4 were sufficiently strong to displace CD80 from the surface of APCs to be internalized by breast cancer cells. We further demonstrated that because of the force-dependent trans-endocytosis of CD80, the capacity of APCs to activate T cells was significantly attenuated. Furthermore, inhibiting force generation in cancer cells would increase the T cell activating capacity of APCs. Our results provide a possible mechanism behind the immunosuppression commonly seen in breast cancer patients, and may lead to a new strategy to restore anti-tumor immunity by inhibiting pathways of force-generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.